Pfizer treats first patient in trial for investigational mini-dystrophin gene therapy for the treatment of Duchenne muscular dystrophy
Pfizer has stated that they have begun their Phase 1b clinical trial for its mini-dystrophin gene therapy candidate, PF-06939926, in patients with Duchenne muscular dystrophy (DMD). The first patient received an infusion of the mini-dystrophin gene, administered under the supervision of principal investigator, Edward Smith, MD, Associate Professor of Pediatrics and Neurology at Duke University